Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults

Pneumococcal disease is one of the most common and severe vaccine-preventable diseases (VPDs). Despite the advances in antimicrobial treatment, pneumococcal disease still remains a global burden and exhibits a high mortality rate among people of all ages worldwide. The immunization program of the pn...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nobuhiro Asai, Hiroshige Mikamo
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	pneumococcal vaccine PCV13 PPSV23 invasive pneumococcal disease <i>streptococcus pneumonia</i> Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/4bca337e6edd4a2e8257e2bb4e6325c8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4bca337e6edd4a2e8257e2bb4e6325c8
record_format	dspace
spelling	oai:doaj.org-article:4bca337e6edd4a2e8257e2bb4e6325c82021-11-25T18:25:18ZRecent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults10.3390/microorganisms91123422076-2607https://doaj.org/article/4bca337e6edd4a2e8257e2bb4e6325c82021-11-01T00:00:00Zhttps://www.mdpi.com/2076-2607/9/11/2342https://doaj.org/toc/2076-2607Pneumococcal disease is one of the most common and severe vaccine-preventable diseases (VPDs). Despite the advances in antimicrobial treatment, pneumococcal disease still remains a global burden and exhibits a high mortality rate among people of all ages worldwide. The immunization program of the pneumococcal conjugate vaccine (PCV) in children has decreased pneumococcal disease incidence in several countries. However, there are several problems regarding the pneumococcal vaccine, such as indications for immunocompetent persons with underlying medical conditions with a risk of pneumococcal disease, the balance of utility and cost, i.e., cost-effectiveness, vaccine coverage rate, serotype replacement, and adverse events. Especially for individuals aged 19–64 at risk of pneumococcal disease, physicians and vaccine providers should make a rational decision whether the patients should be vaccinated or not, since there is insufficient evidence supporting it. We describe this review regarding topics and problems regarding pneumococcal vaccination from the clinician’s point of view.Nobuhiro AsaiHiroshige MikamoMDPI AGarticlepneumococcal vaccinePCV13PPSV23invasive pneumococcal disease<i>streptococcus pneumonia</i>Biology (General)QH301-705.5ENMicroorganisms, Vol 9, Iss 2342, p 2342 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	pneumococcal vaccine PCV13 PPSV23 invasive pneumococcal disease <i>streptococcus pneumonia</i> Biology (General) QH301-705.5
spellingShingle	pneumococcal vaccine PCV13 PPSV23 invasive pneumococcal disease <i>streptococcus pneumonia</i> Biology (General) QH301-705.5 Nobuhiro Asai Hiroshige Mikamo Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults
description	Pneumococcal disease is one of the most common and severe vaccine-preventable diseases (VPDs). Despite the advances in antimicrobial treatment, pneumococcal disease still remains a global burden and exhibits a high mortality rate among people of all ages worldwide. The immunization program of the pneumococcal conjugate vaccine (PCV) in children has decreased pneumococcal disease incidence in several countries. However, there are several problems regarding the pneumococcal vaccine, such as indications for immunocompetent persons with underlying medical conditions with a risk of pneumococcal disease, the balance of utility and cost, i.e., cost-effectiveness, vaccine coverage rate, serotype replacement, and adverse events. Especially for individuals aged 19–64 at risk of pneumococcal disease, physicians and vaccine providers should make a rational decision whether the patients should be vaccinated or not, since there is insufficient evidence supporting it. We describe this review regarding topics and problems regarding pneumococcal vaccination from the clinician’s point of view.
format	article
author	Nobuhiro Asai Hiroshige Mikamo
author_facet	Nobuhiro Asai Hiroshige Mikamo
author_sort	Nobuhiro Asai
title	Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults
title_short	Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults
title_full	Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults
title_fullStr	Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults
title_full_unstemmed	Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults
title_sort	recent topics of pneumococcal vaccination: indication of pneumococcal vaccine for individuals at a risk of pneumococcal disease in adults
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/4bca337e6edd4a2e8257e2bb4e6325c8
work_keys_str_mv	AT nobuhiroasai recenttopicsofpneumococcalvaccinationindicationofpneumococcalvaccineforindividualsatariskofpneumococcaldiseaseinadults AT hiroshigemikamo recenttopicsofpneumococcalvaccinationindicationofpneumococcalvaccineforindividualsatariskofpneumococcaldiseaseinadults
_version_	1718411192426299392

Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults

Ejemplares similares